Health Canada has announced that it is withdrawing marketing authorization for calcitonin nasal sprays as of October 1, 2013 due to concerns about cancer risks associated with the products. Injectable calcitonin products will continue to be available with additional warnings on the labels. The agency announced in July 2012 that it would conduct a safety review of calcitonin nasal sprays.
In the US, an FDA advisory committee warned in March 2013 that the risks of calcitonin nasal spray outweighed its benefits for the treatment of osteoporosis. In Europe, the EMA recommended against use of the products in July 2012.
Read the Health Canada announcement.
